Arix Bioscience PLC

Scheme Effective

Suspension of Trading in Shares

Transaction Update

Results of First General Meeting

Holding(s) in Company

Holding(s) in Company

Update on the Scheme and Publication of Notice of Second General Meeting

Update on the Scheme and Resignation of Directors

Financial update on Harpoon Therapeutics acquisition by Merck (MSD)

Unaudited NAV for December 2023

Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD)

Publication of Circular and RTW Bio Prospectus

Holding(s) in Company

Update regarding timing of Proposed Scheme of Reconstruction

Unaudited NAV for November 2023

Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial

Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock

PDMR Notification & Director Shareholding

Unaudited NAV for October 2023

PDMR Notification & Director Shareholding

PDMR Notification & Director Shareholding

Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102

Portfolio company Harpoon Therapeutics announces up to $150 million private placement

Unaudited NAV for September 2023

Interim Results for the Six Months Ended 30 June 2023

Board Change

Notice of Results and Investor Presentation

Unaudited NAV for August 2023

Unaudited NAV for July 2023